Relypsa (RLYP) Misses Q4 EPS by 5c; Provides 'Encouraging' Initial Veltassa Script Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Relypsa Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Other Corporate Updates
February 24, 2016 4:05 PM ESTRelypsa reports encouraging initial demand for VeltassaVeltassa added to CMS 2016 Formulary Reference File and agreements signed with Express Scripts and CVS Caremark, the two largest pharmacy benefit managers in the United StatesRelypsa plans to submit a supplemental New Drug Application (sNDA) by mid-2016 requesting a label change for Veltassa based on positive results of Phase 1 drug-drug interaction studiesRelypsa and VFMCRP on track to submit European application for Veltassa in first half of 2016Relypsa management to host conference call/webcast this afternoon at 5:00 p.m. ET/2:00... More
